- News Home
6 March 2014 1:04 pm ,
Vol. 343 ,
Antiretroviral drugs can protect people from becoming infected by HIV. But so-called pre-exposure prophylaxis, or PrEP...
Two studies show that eating a diet low in protein and high in carbohydrates is linked to a longer, healthier life, and...
Considered an icon of conservation science, researchers at World Wildlife Fund (WWF) headquarters in Washington, D.C.,...
The new atlas, which shows the distribution of important trace metals and other substances, is the first product of...
Early in April, the first of a fleet of environmental monitoring satellites will lift off from Europe's spaceport in...
Since 2000, U.S. government health research agencies have spent almost $1 billion on an effort to churn out thousands...
Magdalena Koziol, a former postdoc at Yale University, was the victim of scientific sabotage. Now, she is suing the...
- 6 March 2014 1:04 pm , Vol. 343 , #6175
- About Us
FDA Pulls Avastin for Breast Cancer
18 November 2011 12:48 pm
The U.S. Food and Drug Administration (FDA) announced today that it was stripping the drug Avastin of its approval for use to treat breast cancer. The move comes 4 months after an FDA advisory committee agreed that Avastin, approved for breast cancer in 2008, doesn't help that disease after all.
Today's announcement, by FDA Commissioner Margaret Hamburg, isn't much of a surprise. In part, that's because FDA usually follows its advisory committees' recommendations. But at a high-stakes June hearing, FDA officials had also argued that rescinding Avastin's approval for breast cancer was the right thing to do. The drug was approved under a "fast-track" program at FDA, which aims to get drugs out more quickly to people who need them. But it also means therapies are approved with less clinical data under their belt, and that was the case with Avastin. FDA gave its blessing based on a trial showing it offered breast cancer patients an extra 5.5 months of "progression-free survival," time when their tumors weren't growing. Subsequent trials showed a more modest benefit, in one case of less than a month, and the drug has serious side effects.
Avastin will remain on the market for several other cancers.